ArticleTranslational lung cancer research2019

Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study).

Masahiro Iwasaku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.